Balance Sheet
Cash Flow Statement
Cash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Amortization of Deferred Charges (2021 - 2023)

Alaunos Therapeutics (TCRT) has disclosed Amortization of Deferred Charges for 3 consecutive years, with $867000.0 as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Amortization of Deferred Charges rose 318.84% year-over-year to $867000.0, compared with a TTM value of $867000.0 through Mar 2024, down 30.92%, and an annual FY2023 reading of $1.3 million, up 36.49% over the prior year.
  • Amortization of Deferred Charges was $867000.0 for Q2 2023 at Alaunos Therapeutics, up from $472000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $867000.0 in Q2 2023 and bottomed at $148000.0 in Q3 2021.
  • Average Amortization of Deferred Charges over 3 years is $337875.0, with a median of $232000.0 recorded in 2021.
  • The sharpest move saw Amortization of Deferred Charges soared 47.66% in 2022, then surged 318.84% in 2023.
  • Year by year, Amortization of Deferred Charges stood at $235000.0 in 2021, then skyrocketed by 47.66% to $347000.0 in 2022, then skyrocketed by 149.86% to $867000.0 in 2023.
  • Business Quant data shows Amortization of Deferred Charges for TCRT at $867000.0 in Q2 2023, $472000.0 in Q1 2023, and $347000.0 in Q4 2022.